{"id":1841,"date":"2026-06-15T10:02:58","date_gmt":"2026-06-15T01:02:58","guid":{"rendered":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/?p=1841"},"modified":"2026-06-15T10:04:38","modified_gmt":"2026-06-15T01:04:38","slug":"identification-of-novel-small-molecule-inhibitors-targeting-kdm5b-and-evaluation-of-their-antitumour-effects-cancer-med-2026","status":"publish","type":"post","link":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/archives\/1841","title":{"rendered":"Identification of novel small-molecule inhibitors targeting KDM5B and evaluation of their antitumour effects (Cancer Med, 2026)"},"content":{"rendered":"<p><strong>Identification of novel small-molecule inhibitors targeting KDM5B and evaluation of their antitumour effects\u00a0(Cancer Med, 2026)<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>Dr. Hara et al. identified a novel series of KDM5B inhibitors through structure-based optimization following screening of compounds targeting the histone demethylase KDM5B, a key epigenetic regulator implicated in cancer. Lead compounds exhibited potent KDM5B inhibition, low-micromolar antiproliferative activity across the cancer cell panel, and significant antitumour efficacy in xenograft models. Notably, we demonstrated enhanced tumour suppression and, when combined with RNA-based in vivo CAR-T cell therapy, induced chromatin accessibility changes in tumour and immune cell populations. These findings highlight a promising epigenetic therapeutic candidate that potentiates antitumour immunity through chromatin remodelling. Thus, discovery of a potent KDM5B inhibitor that rewires chromatin accessibility and augments antitumour responses, provides a new avenue for epigenetic cancer immunotherapy.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Identification of novel small-molecule inhibitors targeting KDM5B and evaluation of their antitumour effects\u00a0( &hellip; <a href=\"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/archives\/1841\" class=\"more-link\"><span class=\"screen-reader-text\">&#8220;Identification of novel small-molecule inhibitors targeting KDM5B and evaluation of their antitumour effects (Cancer Med, 2026)&#8221; \u306e<\/span>\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-1841","post","type-post","status-publish","format-standard","hentry","category-results"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/posts\/1841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/comments?post=1841"}],"version-history":[{"count":5,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/posts\/1841\/revisions"}],"predecessor-version":[{"id":1848,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/posts\/1841\/revisions\/1848"}],"wp:attachment":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/media?parent=1841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/categories?post=1841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/mds\/wp-json\/wp\/v2\/tags?post=1841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}